Loading...
XSHE300009
Market cap1.84bUSD
Jan 15, Last price  
8.26CNY
1D
-1.08%
1Q
-6.14%
Jan 2017
10.00%
IPO
156.68%
Name

Anhui Anke Biotechnology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300009 chart
P/E
15.90
P/S
4.70
EPS
0.52
Div Yield, %
3.05%
Shrs. gr., 5y
0.69%
Rev. gr., 5y
14.42%
Revenues
2.87b
+22.94%
127,769,584125,874,083156,490,022190,643,971227,930,127267,916,554337,940,099430,346,122542,405,933635,755,075849,216,4341,096,268,3151,461,550,2031,712,529,6691,701,417,2162,168,765,2052,331,062,7272,865,752,059
Net income
847m
+20.47%
15,727,07822,713,57234,552,89444,570,47151,983,69163,322,66073,945,18289,870,067109,851,477136,254,700197,302,805277,742,623263,171,602124,465,864358,955,394206,629,495703,260,285847,229,426
CFO
985m
+40.92%
29,662,11435,098,07926,043,95438,674,86547,427,2117,180,61153,800,82553,213,032108,684,214118,734,165258,005,072280,625,013287,490,590295,627,531464,796,376592,171,625698,977,608985,011,682
Dividend
May 27, 20240.25 CNY/sh
Earnings
Apr 18, 2025

Profile

Anhui Anke Biotechnology (Group) Co., Ltd. develops, produces, and markets pharmaceutical products in China and internationally. The company offers recombinant human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It also provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, sperm DNA fragmentation staining, and leptin and immunohistochemical diagnostic kits. In addition, the company offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care and anti-aging products; and synthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, it provides autosomal, sex chromosome, autosomal and sex chromosome combination, and other kits, as well as paternity testing set packages; tumor biological immunotherapy products; and DNA testing professional services. The company was founded in 2000 and is based in Hefei, China.
URL
https://www.ankebio.com/
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,865,752
22.94%
2,331,063
7.48%
Cost of revenue
1,458,980
1,436,999
Unusual Expense (Income)
NOPBT
1,406,773
894,063
NOPBT Margin
49.09%
38.35%
Operating Taxes
61,341
96,129
Tax Rate
4.36%
10.75%
NOPAT
1,345,432
797,935
Net income
847,229
20.47%
703,260
240.35%
Dividends
(411,050)
(327,542)
Dividend yield
2.46%
2.14%
Proceeds from repurchase of equity
(3,000)
BB yield
0.02%
Debt
Debt current
9,081
Long-term debt
95,635
48,126
Deferred revenue
114,162
Other long-term liabilities
113,522
2
Net debt
(1,764,548)
(1,110,286)
Cash flow
Cash from operating activities
985,012
698,978
CAPEX
(195,336)
Cash from investing activities
(643,018)
Cash from financing activities
(407,289)
FCF
1,097,387
597,409
Balance
Cash
1,455,799
1,167,492
Long term investments
404,383
Excess cash
1,716,894
1,050,939
Stockholders' equity
3,565,427
3,312,271
Invested Capital
2,376,777
2,426,877
ROIC
56.02%
36.93%
ROCE
34.28%
25.42%
EV
Common stock shares outstanding
1,634,278
1,635,489
Price
10.22
9.19%
9.36
-28.50%
Market cap
16,702,323
9.11%
15,308,177
-28.62%
EV
15,132,708
14,390,979
EBITDA
1,509,825
980,638
EV/EBITDA
10.02
14.68
Interest
2,941
1,522
Interest/NOPBT
0.21%
0.17%